The partnership aims to digitise musculoskeletal care, by leveraging objective data, selecting the best treatment methods for OA, to endure better patient outcomes and reduced costs
AI-based medical device company OPUM has teamed up with orthopaedic bracing manufacturer Thuasne to develop a digital solution for the non-invasive treatment of osteoarthritis (OA).
The partnership aims to digitise musculoskeletal care, by leveraging objective data, selecting the best treatment methods for OA, to endure better patient outcomes and reduced costs.
Thuasne is engaged in imagining, developing and manufacturing medical devices, in the fields of orthopaedics, medical compression, home care and sports.
As part of the partnership, the initial product is expected to integrate OPUM’s AI-enabled Digital Knee care platform with Thuasne’s Rebel Reliever OA knee brace.
Thuasne innovation director Matthieu Ducottet said: “We are thrilled to announce this partnership with OPUM which will be harnessing the power of our flagship Rebel Reliever OA knee brace and our trusted Townsend Motion hinge.
“Combining emerging digital solutions with industry-leading technology is an exciting prospect and we look forward to the opportunities ahead.”
When combined, the technologies from OPUM and Thuasne are anticipated to deliver personalised exercise and behavioural therapies directly to the patient.
Also, they would allow remote monitoring at scale, enabling clinicians to manage more patients with a higher quality of personalised care, said the company.
The Digital Knee Rebel Reliever is currently deployed at the Shirley Ryan AbilityLab, and other sites in the US, with plans to widely commercialise in the fourth quarter of 2021.
Established in 2016, OPUM offers an AI-driven platform that enables optimal delivery of care by reducing prescription burden, allowing for personalised care plans.
OPUM CEO Andrew McDaid said: “This partnership is a key part of our vision to deliver scalable personalized musculoskeletal care to positively impact the lives of patients around the world.
“Our solution spans the joint health continuum helping guide patients, and their providers, from initial onset through optimally prescribed interventions to reach their goals.”